Background: Novel oncologic therapies, including epidermal growth factor receptor inhibitors (EGFR-Is) and immune checkpoint inhibitors (ICIs), are associated with a new spectrum of adverse reactions, with prominent cutaneous toxicities. The impact of cutaneous adverse events (cAEs) on patients’ quality of life (QoL) represents an unmet clinical need. Objectives: The aims of this study were (1) to assess whether cutaneous toxicities directed therapies are effective in reducing the QoL burden via the submission of 2 patient reported outcome measures (PROMs); (2) to investigate whether class of oncologic therapy, type of cAE and toxicity severity differently impact on patients’ QoL. Methods: A prospective observational study was conducted at the Dermatology department of the Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, from October 2018 to October 2019. Patients aged ≥18 years, under therapy with EGFR-Is or ICIs and experiencing a treatment-related cAE were eligible for the study. Dermatology Life Quality Index (DLQI) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30 version 3.0 (EORTC QLQ-C30) were administered to patients at first clinical visit (T0), at 1-month (T1), and at 3-month (T2) dermatological follow-up. Results: Sixty cAEs of 51 patients have been recorded. A significant difference in the mean score for both DLQI and EORTC QLQ-C30 was found along the 3-months dermatological follow-up (p < 0.0001). A similar QoL improvement was reported for PROMs stratified by class of therapy and toxicity severity (p < 0.0001). No difference was reported for patients with pyogenic granuloma-like lesions and psoriasiform eruption as per DLQI. Class of therapy and toxicity severity did not differently impact on patients’ QoL at selected timepoints; we reported a higher EORTC QLQ-C30 score at T2 for patients developing psoriasiform eruption compared to other types of cAEs. Conclusions: Early patients’ referral to dermatologists and tailored management could result in better QoL.

1.
Jonker
DJ
,
O’Callaghan
CJ
,
Karapetis
CS
,
Zalcberg
JR
,
Tu
D
,
Au
HJ
, et al
.
Cetuximab for the treatment of colorectal cancer
.
N Engl J Med
.
2007
;
357
(
20
):
2040
8
.
2.
Robert
C
,
Schachter
J
,
Long
GV
,
Arance
A
,
Grob
JJ
,
Mortier
L
, et al
.
Pembrolizumab versus ipilimumab in advanced melanoma
.
N Engl J Med
.
2015
;
372
(
26
):
2521
32
.
3.
Herbst
RS
,
Baas
P
,
Kim
DW
,
Felip
E
,
Pérez-Gracia
JL
,
Han
JY
, et al
.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
.
Lancet
.
2016
;
387
(
10027
):
1540
50
.
4.
Ferris
RL
,
Blumenschein
G
,
Fayette
J
,
Guigay
J
,
Colevas
AD
,
Licitra
L
, et al
.
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
.
N Engl J Med
.
2016
;
375
(
19
):
1856
67
.
5.
Motzer
RJ
,
Escudier
B
,
McDermott
DF
,
George
S
,
Hammers
HJ
,
Srinivas
S
, et al
.
Nivolumab versus everolimus in advanced renal-cell carcinoma
.
N Engl J Med
.
2015
;
373
(
19
):
1803
13
.
6.
Pardoll
DM
.
The blockade of immune checkpoints in cancer immunotherapy
.
Nat Rev Cancer
.
2012
;
12
(
4
):
252
64
.
7.
Mendelsohn
J
,
Baselga
J
.
The EGF receptor family as targets for cancer therapy
.
Oncogene
.
2000
;
19
(
56
):
6550
65
.
8.
Balagula
Y
,
Garbe
C
,
Myskowski
PL
,
Hauschild
A
,
Rapoport
BL
,
Boers-Doets
CB
, et al
.
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
.
Int J Dermatol
.
2011
;
50
(
2
):
129
46
.
9.
Postow
MA
,
Sidlow
R
,
Hellmann
MD
.
Immune-related adverse events associated with immune checkpoint blockade
.
N Engl J Med
.
2018
;
378
(
2
):
158
68
.
10.
Hu
JC
,
Sadeghi
P
,
Pinter-Brown
LC
,
Yashar
S
,
Chiu
MW
.
Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management
.
J Am Acad Dermatol
.
2007
;
56
(
2
):
317
26
.
11.
Sibaud
V
.
Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy
.
Am J Clin Dermatol
.
2018
;
19
(
3
):
345
61
.
12.
Terrier
B
,
Humbert
S
,
Preta
LH
,
Delage
L
,
Razanamahery
J
,
Laurent-Roussel
S
, et al
.
Risk of scleroderma according to the type of immune checkpoint inhibitors
.
Autoimmun Rev
.
2020
;
19
(
8
):
102596
.
13.
De Simone
C
,
Mannino
M
,
Sollena
P
,
Deilhes
F
,
Sibaud
V
,
Peris
K
.
Morphea-like changes in the setting of cancer immunotherapy
.
J Eur Acad Dermatol Venereol
.
2021
;
35
(
10
):
e684
5
.
14.
Common Terminology Criteria for Adverse Events (CTCAE) Version5
.
National Cancer Institute, US Department of Health and Human Services, National Institutes of Health
. Published: November 27.
15.
Tischer
B
,
Huber
R
,
Kraemer
M
,
Lacouture
ME
.
Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
.
Support Care Cancer
.
2017
;
25
(
2
):
651
60
.
16.
Trotti
A
,
Colevas
AD
,
Setser
A
,
Basch
E
.
Patient-reported outcomes and the evolution of adverse event reporting in oncology
.
J Clin Oncol
.
2007
;
25
(
32
):
5121
7
.
17.
Rosen
AC
,
Case
EC
,
Dusza
SW
,
Balagula
Y
,
Gordon
J
,
West
DP
, et al
.
Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic
.
Am J Clin Dermatol
.
2013
;
14
(
4
):
327
33
.
18.
Joshi
SS
,
Ortiz
S
,
Witherspoon
JN
,
Rademaker
A
,
West
DP
,
Anderson
R
, et al
.
Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life
.
Cancer
.
2010
;
116
(
16
):
3916
23
.
19.
Finlay
AY
,
Khan
GK
.
Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use
.
Clin Exp Dermatol
.
1994
;
19
(
3
):
210
6
.
20.
Aaronson
NK
,
Ahmedzai
S
,
Bergman
B
,
Bullinger
M
,
Cull
A
,
Duez
NJ
, et al
.
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
.
J Natl Cancer Inst
.
1993
;
85
(
5
):
365
76
.
21.
Hongbo
Y
,
Thomas
CL
,
Harrison
MA
,
Salek
MS
,
Finlay
AY
.
Translating the science of quality of life into practice: what do dermatology life quality index scores mean
.
J Invest Dermatol
.
2005
;
125
(
4
):
659
64
.
22.
Suh Oh
HJ
,
Flórez Menéndez
Á
,
Sacristán Santos
V
,
Fernández Ribeiro
F
,
Vilanova-Trillo
L
,
Constenla Figueiras
M
, et al
.
Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study
.
Drugs Context
.
2020
;
9
:
2020–6–6
.
23.
Hofmann
L
,
Forschner
A
,
Loquai
C
,
Goldinger
SM
,
Zimmer
L
,
Ugurel
S
, et al
.
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
.
Eur J Cancer
.
2016
;
60
:
190
209
.
24.
Balagula
Y
,
Rosen
ST
,
Lacouture
ME
.
The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies
.
J Am Acad Dermatol
.
2011
;
65
(
3
):
624
35
.
25.
Lacouture
ME
,
Basti
S
,
Patel
J
,
Benson
A
3rd
.
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors
.
J Support Oncol
.
2006
;
4
(
5
):
236
8
.
26.
Hassel
JC
,
Kripp
M
,
Al-Batran
S
,
Hofheinz
RD
.
Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists
.
Onkologie
.
2010
;
33
(
3
):
94
8
.
27.
Chen
ST
,
Molina
GE
,
Lo
JA
,
Durbin
S
,
Cohen
JV
,
Reynolds
KL
, et al
.
Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: a retrospective cohort study
.
J Am Acad Dermatol
.
2020
;
82
(
4
):
994
6
.
28.
Thompson
LL
,
Li
EB
,
Krasnow
NA
,
Chang
MS
,
Said
JT
,
Molina
GE
, et al
.
Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity
.
Br J Dermatol
.
2021
;
185
(
3
):
627
35
.
29.
Lee
J
,
Lim
J
,
Park
JS
,
Kim
M
,
Kim
TY
,
Kim
TM
, et al
.
The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study
.
Cancer Res Treat
.
2018
;
50
(
4
):
1186
93
.
30.
Segaert
S
,
Van Cutsem
E
.
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
.
Ann Oncol
.
2005
;
16
(
9
):
1425
33
.
31.
Lacouture
ME
.
Mechanisms of cutaneous toxicities to EGFR inhibitors
.
Nat Rev Cancer
.
2006
;
6
(
10
):
803
12
.
32.
Salman
A
,
Kurt
E
,
Topcuoglu
V
,
Demircay
Z
.
Social anxiety and quality of life in vitiligo and acne patients with facial involvement: a cross-sectional controlled study
.
Am J Clin Dermatol
.
2016
;
17
(
3
):
305
11
.
33.
Apalla
Z
,
Rapoport
B
,
Sibaud
V
.
Dermatologic immune-related adverse events: the toxicity spectrum and recommendations for management
.
Int J Womens Dermatol
.
2021
;
7
(
5Part A
):
625
35
.
34.
Tischer
B
,
Bilang
M
,
Kraemer
M
,
Ronga
P
,
Lacouture
ME
.
A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies
.
Support Care Cancer
.
2018
;
26
(
4
):
1169
79
.
You do not currently have access to this content.